Literature DB >> 2096157

Evaluation of clonidine suppression and various provocation tests in the diagnosis of pheochromocytoma.

H Koshida1, I Miyamori, R Soma, T Matsubara, S Okamoto, M Ikeda, R Takeda.   

Abstract

Recent investigations have shown that the widely used clonidine suppression test is sometimes fallible for the diagnosis of pheochromocytoma. A comparative assessment was made of the following suppression and provocation tests, the clonidine suppression test, and the glucagon, metoclopramide, and naloxone provocation tests. The assessment was performed in 6 patients with pheochromocytoma and in 19 patients without pheochromocytoma who were initially suspected of harboring a tumor. BP response did not predict the presence of pheochromocytoma in any test. Plasma norepinephrine (NE) concentrations determined at 120 and 180 min after oral 150 micrograms of clonidine gave false negative results in 2 of the 5 patients with pheochromocytoma tested. Both plasma NE and epinephrine (E) concentrations were measured before and sequentially after each provocative agent. Neither NE nor E responded to 1 mg of glucagon iv in 2 of the 4 patients with pheochromocytoma tested. Determination of the peak level, peak increment, and % peak increment of NE and E following 10 mg of naloxone iv did not distinguish the two groups. The % peak increments of both NE and E in all 4 patients with pheochromocytoma given 5 mg of metoclopramide iv exceeded the mean + 3 SD values of the patients without pheochromocytoma (25 + 28% for NE, and 25 + 42% for E). These results suggested that, when performed with judicious patient selection (ambiguous plasma or urinary catecholamine levels), the measurement of plasma catecholamines in response to metoclopramide can be a useful adjunctive tool in the diagnosis of pheochromocytoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2096157     DOI: 10.1007/BF03349626

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  24 in total

1.  Comparative effects of prazosin and phenoxybenzamine on arterial blood pressure, heart rate, and plasma catecholamines in essential hypertension.

Authors:  J Mulvihill-Wilson; R M Graham; W Pettinger; C Muckleroy; S Anderson; F A Gaffney; C G Blomqvist
Journal:  J Cardiovasc Pharmacol       Date:  1979 Nov-Dec       Impact factor: 3.105

2.  Results of screening for phaeochromocytoma in 17 hypertensive patients with episodic symptoms.

Authors:  R D Hull; E Sebel; G S Stokes; J P Chalmers; H Hinterberger
Journal:  Med J Aust       Date:  1974-03-16       Impact factor: 7.738

3.  Diuretic treatment alters clonidine suppression of plasma norepinephrine.

Authors:  T P Hui; L R Krakoff; K Felton; K Yeager
Journal:  Hypertension       Date:  1986-04       Impact factor: 10.190

4.  Fine-needle aspiration of catecholamine-producing adrenal masses: a possibly fatal mistake.

Authors:  S J McCorkell; N L Niles
Journal:  AJR Am J Roentgenol       Date:  1985-07       Impact factor: 3.959

5.  Naloxone administration releases catecholamines.

Authors:  M Mannelli; M Maggi; M L De Feo; S Cuomo; G Forti; F Moroni; G Giusti
Journal:  N Engl J Med       Date:  1983-03-17       Impact factor: 91.245

6.  Postoperative deaths due to unsuspected pheochromocytoma.

Authors:  D A Cross; J S Meyer
Journal:  South Med J       Date:  1977-11       Impact factor: 0.954

7.  Catecholamines and pancreatic hormones during autonomic blockade in exercising man.

Authors:  H Galbo; N J Christensen; J J Holst
Journal:  Acta Physiol Scand       Date:  1977-12

8.  Evaluation of the clonidine-suppression test in the diagnosis of pheochromocytoma.

Authors:  G Plewe; U Krause; U Cordes; J Beyer
Journal:  Klin Wochenschr       Date:  1988-09-01

9.  Clinically unsuspected pheochromocytomas. Experience at Henry Ford Hospital and a review of the literature.

Authors:  N K Krane
Journal:  Arch Intern Med       Date:  1986-01

10.  Clonidine suppression test for pheochromocytoma: examples of misleading results.

Authors:  H C Taylor; D Mayes; A H Anton
Journal:  J Clin Endocrinol Metab       Date:  1986-07       Impact factor: 5.958

View more
  2 in total

Review 1.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 2.  Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing.

Authors:  Graeme Eisenhofer; Barbara Klink; Susan Richter; Jacques Wm Lenders; Mercedes Robledo
Journal:  Clin Biochem Rev       Date:  2017-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.